Nuclear medicine review. Central & Eastern Europe
-
Nucl Med Rev Cent East Eur · Jan 2010
The value of the Duke Activity Status Index (DASI) in predicting ischaemia in myocardial perfusion scintigraphy - a prospective study.
Functional capacity assessment may be a useful tool to stratify patients according to risk of coronary artery disease (CAD). The Duke Activity Status Index (DASI) is a functional assessment based on activities of daily living and cardiovascular fitness, assessed using a self-administered questionnaire. ⋯ Our study findings suggest that the DASI may represent a powerful tool for risk stratification prior to investigation of CAD. A further study with a larger sample size will be required to investigate the predictive value of the DASI and the association with LVEF.
-
Nucl Med Rev Cent East Eur · Jan 2009
Perfusion computed tomography in prediction of functional outcome in patients with acute ischaemic stroke.
To determine the value of perfusion computed tomography (CT) in prediction of the clinical course and late functional outcome in patients with acute ischaemic stroke who had unremarkable initial brain CT examination. ⋯ In patients within the first 6 hours from stroke onset, and without a hypodensity sign on initial routine CT examination, perfusion CT provides quantitative parameters that correlate well with initial neurological status and late functional outcome.
-
Nucl Med Rev Cent East Eur · Jan 2008
The role of PET/CT in evaluation of Facet and Disc abnormalities in patients with low back pain using (18)F-Fluoride.
Bone scintigraphy including Single Photon Emission Computed Tomography (SPECT) is known for its role in the diagnosis of low back pain disorders. Positron Emission Tomography (PET) with (18)F (Flouride-18) as a tracer can be used to carry out bone scans with improved image quality. With the addition of CT, simultaneous PET/CT fused images provide more accurate anatomical details. The objectives of this work are to assess the use of (18)F-PET/CT in patients with back pain and suspected facetogenic pain, and to find the frequency of facet arthropathy versus disc disease abnormalities. ⋯ (18)F-PET/CT has a potential use in evaluating adult patients with back pain. It has a promising role in identifying causes of persistent back pain following vertebral surgical interventions.
-
Nucl Med Rev Cent East Eur · Jan 2008
Case ReportsNeurolymphomatosis detected by (18)F-FDG PET/CT scan - a case report.
Lymphoma involvement of the peripheral nerves is a rare clinical presentation of non-Hodgkin lymphoma. We report the case of a 59-year-old woman with the defect of peripheral motor neuron admitted for PET/CT scan. The scan disclosed increased (18)F-FDG activity along the brachial and lumbar plexuses together with very intense (18)F-FDG uptake in the cervical lymph node masses. The diagnosis, based on the subsequent histopathologic lymph node examination, was diffuse large B-cell lymphoma.
-
Nucl Med Rev Cent East Eur · Jan 2007
Clinical TrialThe prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
To date, Hodgkin's lymphoma (HL) patients have achieved long-term survival of more than 80%. Unfortunately, longer follow-up has shown serious adverse effects of the treatments used. For this reason, therapeutic strategies are becoming more tailored to the individual patient s prognosis. Pre-treatment risk factors for early-stage and advanced-stage HL are well known indicators of prognosis. Recently, early interim (18)F-FDG PET has been shown as a strong and independent predictor of progression-free survival in HL. Our aim was to assess response to therapy by repeating (18)F-FDG-PET/CT after four and six chemotherapy cycles. ⋯ The preliminary data of the present study confirm those of previous published studies about the negative predictive value of (18)F-FDG-PET/CT performed after four and six chemotherapy cycles, which contributed to the decision to stop treatment and to avoid radiotherapy in HL patients. Nonetheless, our preliminary data seems to suggest that only the (18)F-FDG-PET/CT performed after two cycles of chemotherapy (FDG-PET 2) is able to provide the same prognostic information of the FDG-PET 4 and FDG-PET 6 earlier.